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Advancements in ‘omics’ technologies offer opportunities
to complement current approaches in cancer diagnosis and
assessment of response to therapy. While the relatively
mature fields of transcriptomics and proteomics have
demonstrated their utility in cancer diagnosis and prog-
nosis, they typically rely on complicated and demanding
methodologies requiring isolation of intact ribonucleic acid
or protein and then analyses. Metabolomics is an emerging
field with great potential for cancer screening and early
diagnosis. Here metabolites, defined as small molecules
typically less than 1 kDa, are assessed with modern analyti-
cal approaches that can detect thousands of different mole-
cules, and identify informative subsets of manageable size
for use in simpler cost-effective instrumentation in the
field. Cancer cells show substantial perturbations in meta-
bolism such as glycolysis, Warburg effect, and many labora-
tories are now assessing its utility in oncology.
In the case of pancreatic duct adenocarcinoma (PDAC),
this tumor type is the fourth leading cancer worldwide
with less than 6% 5-year survival rate. PDAC is associated
with poor prognosis based on the late stage diagnosis of
the disease, hence being referred to as the “silent killer”.
Current diagnostic tests lack the sensitivity and specificity
to identify markers of early staging, and efforts have been
carried out at Georgetown University to identify metabo-
lomic biomarkers in patient PDAC tissue which then can
be assessed in biofluids such as urine and serum. To assess
the feasibility of biomarker development in PDAC, we
have also taken a mouse models approach using the p48-
Cre/LSL-KrasG12D mouse model. This model shows
malignant progression to PDAC analogous to the human
disease stages via early and late pancreatic intra-epithelial
neoplasia (PanIN) lesions. Serum was collected from mice
with early PanIN lesions (at 3-5 months) and with late
PanIN or invasive PDAC lesions (13-16 months), as deter-
mined by histopathology. Metabolomics analysis of the
serum samples was conducted through Ultra Performance
Liquid Chromatography coupled to Time-of-flight Mass
Spectrometry (QTOF). Multivariate data analysis revealed
distinct metabolic profiles between the pancreatic cancer
progression stages. One of the metabolites was validated
through tandem mass spectrometry and showed increased
circulating levels in mice with late PanIN and PDAC.
Immunohistochemical analysis of pancreatic tissue showed
increased levels of the enzyme, which produces this meta-
bolite, at the late stages of pancreatic cancer, correlating
with circulating metabolite levels. The use of this approach
in developing diagnostic strategies with metabolomics in
the detection of at-risk subjects will be discussed as a com-
plement to genomics approaches.
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